Deals
Deal snapshot: Preparing for submission and potential approval and launch of its Phase III sleep apnea drug, Apnimed is divesting its half of Shionogi-Apnimed Sleep Science for $100m.
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
Deal Snapshot: The French drugmaker gains rights to the anti-CD19xBCMAxCD3 candidate, which is designed to have the benign safety profile considered especially important in immunology.
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
The deal, which is expected to close in the first half of 2026, includes $2bn upfront plus $1bn in milestone related payments.
For $650m up front, Collegium will pair Azstarys, which provides both immediate and extended onset of action, with Jornay PM, its ADHD drug indicated for bedtime dosing.
Since being taken private by B-FLEXION, Paratek has been building out its commercial portfolio and Radius’s osteoporosis drug Tymlos will advance that strategy.
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin even as the Indian drug regulator keeps a watch on advertising activities
Plus deals involving Rapport/Tenacia, Servier/Kyron.bio, Pfizer/Aska, TransCode/Unleashed Immune Oncolytics, Gedeon Richter/Celmatix and recent AI/ML-focused alliances.
As the Danish vaccine maker plots further M&A activity.
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
Deal Snapshot: The Italian specialty pharma is gaining linerixibat, slated for US approval on March 24 and potentially replacing Ocaliva, which was pulled from the market last September.
For $2.5bn, the deal will bring Servier a pediatric glioma drug to sell alongside its own Voranigo, and an early-stage clinical pipeline in oncology.
Investment bankers, advisors and a former CEO shared their insights at BIO’s Investor and Growth Summit about large and mid-sized pharma deal appetites, noting it’s not all about patent cliffs.
Deal Snapshot: The firms will jointly select 15 novel targets against which Tenaya will identify and validate candidates that Alnylam may elect to license for further development
AnaptysBio says it is on track to split into two companies. A spinout will look to partner Phase IIb rosnilimab and focus on earlier-stage candidates, while the other entity will focus on royalty income.
UCB is paying $1bn-plus for global rights to Antengene's ATG-201, an anti-CD19/CD3 T-cell engager, as it looks to build its strength in immunology.